All News

Active Solar Buildings – entirely heated and cooled by solar thermal energy – should become the standard by 2030 if the vision of the EU’s latest Technology Platform is realised.

A group of researchers, led by Mark Pepys, at University College London has designed and chemically synthesised a new drug, which they have shown to reduce heart tissue damage following a heart attack.

Drug companies finally have an incentive to carry out safety testing in children following new EU legislation approved last week.

A laser physicist in Saudi Arabia has devised a workable optical diagnostic tool to detect early cancer - and is now looking for partners to commercialise the technology.

The first protein drug extracted from the milk of a genetically modified animal has finally received European approval.

Scientists from the University of Birmingham, UK, have powered a fuel cell from confectionary waste. They now want to form a consortium with investors and SMEs to apply for an EU Framework grant.

The Open Source software movement has broken the stranglehold of expensive, proprietary products. Could the same thing happen in biotechnology?

The Finnish developers of a new and tiny silicon-based timer circuit are looking for partners with application-specific engineering and marketing expertise to take the product further.

Advances in neuroscience are opening up the treatment options for central nervous system diseases - at the same time as the ageing population is increasing the market for these products.

Microsoft Corp. is spinning out some of its software technology to two small European tech ventures, as part of a program to speed development of innovations from its labs.

Fujeribio Diagnostics, Inc., based in Japan, has bought Swedish CanAg Diagnostics, merging two leading biotechnology companies in cancer diagnosis.

A team of researchers at ORNL has come up with the concept of nanofermentation, and, it seems, plans to use this as a trademark.

On May 26, the US Patent Office issued a preliminary ruling on another long-running patent fight. This battle differs from other high-profile clashes as the challenger is taking on not a big corporate entity, but a broad community of IT researchers and academics.

Europabio thinks that Europe is doing a poor job when it comes to investing in biotechnology.

EU technology policy is moving beyond the numbers game, and getting down to economic basics.